PMC:7441788 / 17667-17857 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T180","span":{"begin":30,"end":35},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T226","span":{"begin":30,"end":35},"obj":"Chemical"},{"id":"T227","span":{"begin":69,"end":74},"obj":"Chemical"},{"id":"T228","span":{"begin":92,"end":97},"obj":"Chemical"}],"attributes":[{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T131","span":{"begin":8,"end":24},"obj":"Sentence"},{"id":"T132","span":{"begin":25,"end":106},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"671","span":{"begin":65,"end":68},"obj":"Chemical"},{"id":"672","span":{"begin":107,"end":110},"obj":"Chemical"}],"attributes":[{"id":"A671","pred":"pubann:denotes","subj":"671","obj":"MESH:D006886"},{"id":"A672","pred":"pubann:denotes","subj":"672","obj":"MESH:D006886"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T118","span":{"begin":180,"end":187},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-PubTator","denotations":[{"id":"671","span":{"begin":65,"end":68},"obj":"Chemical"},{"id":"672","span":{"begin":107,"end":110},"obj":"Chemical"}],"attributes":[{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"MESH:D006886"},{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":8,"end":24},"obj":"Sentence"},{"id":"T132","span":{"begin":25,"end":106},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}

{"project":"2_test","denotations":[{"id":"32496926-32409561-132195703","span":{"begin":20,"end":22},"obj":"32409561"}],"text":"lanced.\nTang et al [54]. Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3"}